Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma

被引：17
作者：
Gautschi, Oliver [1 ]
Menon, Roopika [2 ]
Bertrand, Miriam [2 ]
Murer, Christian [1 ]
Diebold, Joachim [1 ]
机构：
[1] Cantonal Hosp Lucerne, Luzern, Switzerland
[2] NEO New Oncol GmbH, Cologne, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2019.07.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E13 / E15
页数：4
相关论文
共 50 条
  • [31] Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib
    Wu, Jia-Jun
    Tseng, Jeng-Sen
    Zheng, Zhe-Rong
    Chu, Cheng-Hsiang
    Chen, Kun-Chieh
    Lin, Mong-Wei
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Yang, Tsung-Ying
    Yu, Sung-Liang
    Chen, Jin-Shing
    Ho, Chao-Chi
    Chang, Gee-Chen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [32] Low-dose osimertinib in an elderly with EGFR-mutant metastatic lung adenocarcinoma: A case report and literature review
    Dave Yahot, Kemuel
    Dy-Agra, Guinevere
    Luisa Tiambeng, Ma.
    Lynn Co, Jamie
    RESPIROLOGY, 2024, 29 : 83 - 83
  • [33] Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
    Ricciuti, Biagio
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S249 - S252
  • [34] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers Reply
    Schoenfeld, Adam J.
    Yu, Helena A.
    JAMA ONCOLOGY, 2020, 6 (12) : 1983 - 1983
  • [35] Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization
    Bolan, Patrick O.
    Zviran, Asaf
    Brenan, Lisa
    Schiffman, Joshua S.
    Dusaj, Neville
    Goodale, Amy
    Piccioni, Federica
    Johannessen, Cory M.
    Landau, Dan A.
    CELL SYSTEMS, 2020, 10 (01) : 52 - +
  • [36] Effect of P. gingivalis on osimertinib resistance in EGFR-mutant lung cancer
    Li, Wendong
    Rotter-Maskowitz, Aviva
    Zhang, Keqiang
    Massarelli, Erminia
    Potempa, Jan
    Straussman, Ravid
    Raz, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] ERLOTINIB VERSUS RADIATION THERAPY FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MUTANT LUNG ADENOCARCINOMA
    Gerber, Naamit K.
    Yamada, Yoshiya
    Shi, Weiji
    Zhang, Zhigang
    Riely, Gregory
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Rimner, Andreas
    Wu, Abraham J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S902 - S902
  • [38] Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
    Piper-Vallillo, Andrew J.
    Sequist, Lecia, V
    Piotrowska, Zofia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2926 - +
  • [39] Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
    Gerber, Naamit K.
    Yamada, Yoshiya
    Rimner, Andreas
    Shi, Weiji
    Riely, Gregory J.
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Zhang, Zhigang
    Wu, Abraham J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (02): : 322 - 329
  • [40] Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.
    Blakely, Collin M.
    Gubens, Matthew A.
    Allen, Gregory M.
    Shah, Shrusti
    Jereza, Matthew
    Bacaltos, Bianca
    Bandyopadhyay, Sourav
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345